Robert R McWilliams

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. pmc Phase I trial of a pathotropic retroviral vector expressing a cytocidal cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancer
    Evanthia Galanis
    Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Mol Ther 16:979-84. 2008
  2. ncbi request reprint Management of brain metastases from thyroid carcinoma: a study of 16 pathologically confirmed cases over 25 years
    Robert R McWilliams
    Division of Medical Oncology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Cancer 98:356-62. 2003
  3. pmc Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling
    Robert R McWilliams
    Department of Oncology, Mayo Clinic, Rochester, MN, USA
    Eur J Hum Genet 19:472-8. 2011
  4. pmc Obesity adversely affects survival in pancreatic cancer patients
    Robert R McWilliams
    Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 116:5054-62. 2010
  5. pmc Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations and risk for pancreatic adenocarcinoma
    Robert R McWilliams
    Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Cancer 116:203-9. 2010
  6. pmc Polymorphic variants in hereditary pancreatic cancer genes are not associated with pancreatic cancer risk
    Robert R McWilliams
    Department of Oncology, Mayo Clinic, 200 First Street, Southwest, Rochester, MN 55905, USA
    Cancer Epidemiol Biomarkers Prev 18:2549-52. 2009
  7. pmc Nucleotide excision repair pathway polymorphisms and pancreatic cancer risk: evidence for role of MMS19L
    Robert R McWilliams
    Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA
    Cancer Epidemiol Biomarkers Prev 18:1295-302. 2009
  8. pmc Polymorphisms in DNA repair genes, smoking, and pancreatic adenocarcinoma risk
    Robert R McWilliams
    Division of Medical Oncology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA
    Cancer Res 68:4928-35. 2008
  9. doi request reprint Melanoma-induced brain metastases
    Robert R McWilliams
    Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Expert Rev Anticancer Ther 8:743-55. 2008
  10. ncbi request reprint Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer
    Robert R McWilliams
    Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN 55905, USA
    Clin Colorectal Cancer 6:516-21. 2007

Research Grants

  1. Genetic Epidemiology of Young-Onset Pancreatic Cancer
    Robert McWilliams; Fiscal Year: 2007

Detail Information

Publications39

  1. pmc Phase I trial of a pathotropic retroviral vector expressing a cytocidal cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancer
    Evanthia Galanis
    Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Mol Ther 16:979-84. 2008
    ..5 months from treatment initiation. Rexin-G is well tolerated in doses up to 6 x 10(11) CFU in patients with recurrent pancreatic cancer, but there was no evidence of clinical antitumor activity...
  2. ncbi request reprint Management of brain metastases from thyroid carcinoma: a study of 16 pathologically confirmed cases over 25 years
    Robert R McWilliams
    Division of Medical Oncology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Cancer 98:356-62. 2003
    ..To help contribute to the management of this disease entity, the authors present herein what to their knowledge is the largest series reported to date in which all patients had biopsy proven confirmation of their brain metastases...
  3. pmc Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling
    Robert R McWilliams
    Department of Oncology, Mayo Clinic, Rochester, MN, USA
    Eur J Hum Genet 19:472-8. 2011
    ..Carriers of germline mutations of CDKN2A should be counseled to avoid tobacco use to decrease risk of pancreatic cancer in addition to taking measures to decrease melanoma risk...
  4. pmc Obesity adversely affects survival in pancreatic cancer patients
    Robert R McWilliams
    Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 116:5054-62. 2010
    ..The authors assessed the association of BMI with survival in a sample of pancreatic cancer patients and used epidemiologic and clinical information to understand the contribution of diabetes and hyperglycemia...
  5. pmc Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations and risk for pancreatic adenocarcinoma
    Robert R McWilliams
    Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Cancer 116:203-9. 2010
    ..The purpose of this case-control study was to determine whether CFTR mutations confer a higher risk of pancreatic cancer...
  6. pmc Polymorphic variants in hereditary pancreatic cancer genes are not associated with pancreatic cancer risk
    Robert R McWilliams
    Department of Oncology, Mayo Clinic, 200 First Street, Southwest, Rochester, MN 55905, USA
    Cancer Epidemiol Biomarkers Prev 18:2549-52. 2009
    ..We hypothesized that common variants in these genes, single nucleotide polymorphisms (SNP), may also influence risk for pancreatic cancer development...
  7. pmc Nucleotide excision repair pathway polymorphisms and pancreatic cancer risk: evidence for role of MMS19L
    Robert R McWilliams
    Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA
    Cancer Epidemiol Biomarkers Prev 18:1295-302. 2009
    ..Single nucleotide polymorphisms (SNP) in the nucleotide excision repair pathway may encode alterations that affect DNA repair function and therefore influence the risk of pancreatic cancer development...
  8. pmc Polymorphisms in DNA repair genes, smoking, and pancreatic adenocarcinoma risk
    Robert R McWilliams
    Division of Medical Oncology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA
    Cancer Res 68:4928-35. 2008
    ..78; 95% CI, 1.28-6.04) or D711D (OR, 2.19; 95% CI, 1.01-4.73). No other significant differences in risk were identified. Minor alleles in DNA repair genes XPF/ERCC4 and XPD/ERCC2 were associated with altered risk for pancreatic cancer...
  9. doi request reprint Melanoma-induced brain metastases
    Robert R McWilliams
    Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Expert Rev Anticancer Ther 8:743-55. 2008
    ..Future directions include combined-modality therapy, the incorporation of novel agents, and careful consideration of the structure of clinical trials for this disease...
  10. ncbi request reprint Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer
    Robert R McWilliams
    Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN 55905, USA
    Clin Colorectal Cancer 6:516-21. 2007
    ..A combination regimen using all 4 agents could potentially increase response rates in CRC...
  11. ncbi request reprint Risk of malignancy in first-degree relatives of patients with pancreatic carcinoma
    Robert R McWilliams
    Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer 104:388-94. 2005
    ..Counseling the families of PC patients regarding their risk of cancer remains problematic because little information is available...
  12. ncbi request reprint Treatment options for brain metastases from melanoma
    Robert R McWilliams
    Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Expert Rev Anticancer Ther 5:809-20. 2005
    ..Future directions include combined modality therapy, the incorporation of novel agents and careful consideration of the structure of clinical trials for this disease...
  13. pmc Association of family history of specific cancers with a younger age of onset of pancreatic adenocarcinoma
    Robert R McWilliams
    Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Clin Gastroenterol Hepatol 4:1143-7. 2006
    ..Pancreatic adenocarcinoma has been associated with several familial cancer syndromes that also predispose to other malignancies. Younger ages of onset of pancreatic cancer (PC) have been reported in families with these syndromes...
  14. ncbi request reprint Treatment of brain metastases from melanoma
    Robert R McWilliams
    Division of Medical Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 78:1529-36. 2003
    ..Chemotherapy may be gaining a role with newer agents that penetrate the blood-brain barrier. Combined modality therapy appears to be the future direction of treatment of multiple metastases...
  15. ncbi request reprint Novel therapeutics in colorectal cancer
    Robert R McWilliams
    Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Dis Colon Rectum 48:1632-50. 2005
    ..We also suggest appropriate clinical settings for specific targets and outline future directions of research...
  16. pmc Association of breast cancer susceptibility variants with risk of pancreatic cancer
    Fergus J Couch
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Epidemiol Biomarkers Prev 18:3044-8. 2009
    ..Recently, several breast cancer susceptibility loci have been identified through genome-wide association studies. Here we evaluated possible associations between these single nucleotide polymorphisms (SNP) and pancreatic cancer risk...
  17. ncbi request reprint Malignant melanoma in the 21st century, part 2: staging, prognosis, and treatment
    Svetomir N Markovic
    Division of Hematology, College of Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:490-513. 2007
    ..Although much work remains to be done to improve the survival of patients with melanoma, clinically meaningful results seem within reach...
  18. doi request reprint A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775
    Lisa A Kottschade
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Cancer 119:586-92. 2013
    ..Increasing evidence shows chemotherapy in combination with vascular endothelial growth factor (VEGF) inhibition is a clinically active therapy for patients with metastatic melanoma (MM)...
  19. pmc Association of mitotic regulation pathway polymorphisms with pancreatic cancer risk and outcome
    Fergus J Couch
    Department of Laboratory Medicine and Pathology, Stabile 2 42, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA
    Cancer Epidemiol Biomarkers Prev 19:251-7. 2010
    ..Single nucleotide polymorphisms (SNP) in regulators of mitosis may promote chromosome missegregation and influence pancreatic cancer and/or survival...
  20. pmc A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1)
    Lisa A Kottschade
    Mayo Clinic Rochester, Rochester, Minnesota 55905, USA
    Cancer 117:1704-10. 2011
    ..ABI-007 is an albumin-bound formulation of paclitaxel that has demonstrated single-agent activity against metastatic melanoma...
  21. doi request reprint Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005)
    Michele M Corsini
    Department of Radiation Oncology the Division of Gastroenterologic and General Surgery, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 26:3511-6. 2008
    ..To determine prognostic factors and impact of adjuvant chemotherapy (CT) and radiotherapy (RT) on overall survival (OS) after resection of pancreatic adenocarcinoma...
  22. doi request reprint Pilot study of granulocyte-macrophage colony-stimulating factor and interleukin-2 as immune adjuvants for a melanoma peptide vaccine
    Matthew S Block
    Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Melanoma Res 21:438-45. 2011
    ..The increase in T regulatory cells associated with interleukin-2 treatment suggests that interleukin-2 may be immunosuppressive in this setting...
  23. doi request reprint Pemetrexed and gemcitabine for biliary tract and gallbladder carcinomas: a North Central Cancer Treatment Group (NCCTG) phase I and II Trial, N9943
    Steven R Alberts
    Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    J Gastrointest Cancer 38:87-94. 2007
    ..To determine the maximum tolerated dose (MTD) and efficacy of pemetrexed and gemcitabine in patients with either biliary tract or gallbladder carcinoma...
  24. ncbi request reprint Fluctuation of systemic immunity in melanoma and implications for timing of therapy
    Alexey A Leontovich
    Department of Health Science Research, Mayo Clinic, Rochester, MN 55901, USA
    Front Biosci (Elite Ed) 4:958-75. 2012
    ..Individualized conventional chemotherapy delivery by synchronizing treatment with pre-existing patient-specific biorhythms may improve clinical outcomes in metastatic melanoma...
  25. doi request reprint A single-institution experience with 491 cases of small bowel adenocarcinoma
    Thorvardur R Halfdanarson
    Department of Oncology, Mayo Clinic, Rochester, MN, USA
    Am J Surg 199:797-803. 2010
    ..The optimal treatment of small bowel adenocarcinoma is unknown...
  26. ncbi request reprint A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma
    Svetomir N Markovic
    Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Am J Clin Oncol 30:303-9. 2007
    ..We conducted a phase II trial evaluating the clinical efficacy of ABT-510 and its effects on biomarkers of angiogenesis and immunity in patients with metastatic melanoma (MM)...
  27. pmc A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33
    Gloria M Petersen
    Department of Health Sciences Research, College of Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Nat Genet 42:224-8. 2010
    ..19, 95% CI 1.11-1.27), maps to the CLPTM1L-TERT locus on 5p15.33, which is associated with multiple cancers. Our study has identified common susceptibility loci for pancreatic cancer that warrant follow-up studies...
  28. doi request reprint Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: a systematic review and meta-analysis
    Siddharth Singh
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Gastroenterol 108:510-9; quiz 520. 2013
    ..We performed a systematic review and meta-analysis evaluating the effect of metformin, sulfonylureas (SUs), thiazolidinediones (TZDs), and insulin on the risk of PaC in patients with diabetes mellitus (DM)...
  29. doi request reprint Are cancer survivors/patients knowledgeable about osteoporosis? Results from a survey of 285 chemotherapy-treated cancer patients and their companions
    Heidi McKean
    Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Nutr Educ Behav 40:144-8. 2008
    ..This study assessed osteoporosis knowledge deficits among cancer patients and their spouses/partners...
  30. ncbi request reprint Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis
    Svetomir N Markovic
    Division of Hematology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:364-80. 2007
    ..Part 2 (which will appear in the April 2007 issue) will review melanoma staging, prognosis, and treatment...
  31. doi request reprint Genes-Environment Interactions in Obesity- and Diabetes-Associated Pancreatic Cancer: A GWAS Data Analysis
    Hongwei Tang
    Authors Affiliations Departments of Gastrointestinal Medical Oncology and Epidemiology, The University of Texas MD Anderson Cancer Center Division of Biostatistics and Human Genetics Center, School of Public Health, University of Texas Health Science Center, Houston, Texas Catalan Institute of Oncology ICO IDIBELL, Barcelona, Spain Yale University School of Public Health, New Haven, Connecticut Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York National Institute for Public Health and the Environment RIVM, Bilthoven and Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands Samuel Lunenfeld Research Institute, Toronto General Hospital, University of Toronto, Toronto, Canada Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota International Agency for Research on Cancer, Lyon Institut national de la santé et de la recherche medicale INSERM, Centre for Research in Epidemiology and Population Health CESP, U1018, Nutrition, Hormones and Women s Health team Univ Paris Sud, UMRS 1018 IGR, F 94805, Villejuif, France Division of Epidemiology, Public Health, and Primary Care, Imperial College London, Suwa Red Cross Hospital
    Cancer Epidemiol Biomarkers Prev 23:98-106. 2014
    ..Obesity and diabetes are potentially alterable risk factors for pancreatic cancer. Genetic factors that modify the associations of obesity and diabetes with pancreatic cancer have previously not been examined at the genome-wide level...
  32. pmc Factors influencing receptivity to future screening options for pancreatic cancer in those with and without pancreatic cancer family history
    Carmen Radecki Breitkopf
    Mayo Clinic College of Medicine, Department of Health Sciences Research, Charlton 6, 200 First Street SW, Rochester, MN, 55905, USA
    Hered Cancer Clin Pract 10:8. 2012
    ..abstract:..
  33. pmc GLI1 inhibition promotes epithelial-to-mesenchymal transition in pancreatic cancer cells
    Simon Joost
    Institute of Molecular Biology and Tumor Research, Philipps University, Marburg, Germany
    Cancer Res 72:88-99. 2012
    ....
  34. pmc Malignant melanoma in the 21st century: the emerging molecular landscape
    Aleksandar Sekulic
    Department of Dermatology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Mayo Clin Proc 83:825-46. 2008
    ..We review the emerging molecular landscape of melanoma and its implications for better management of patients with melanoma...
  35. pmc Fluorescence in situ hybridization to visualize genetic abnormalities in interphase cells of acinar cell carcinoma, ductal adenocarcinoma, and islet cell carcinoma of the pancreas
    Gordon W Dewald
    Division of Laboratory Genetics, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 84:801-10. 2009
    ..To use fluorescence in situ hybridization (FISH) to visualize genetic abnormalities in interphase cell nuclei (interphase FISH) of acinar cell carcinoma, ductal adenocarcinoma, and islet cell carcinoma of the pancreas...
  36. doi request reprint Percutaneous cryoablation of musculoskeletal oligometastatic disease for complete remission
    Brendan P McMenomy
    Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
    J Vasc Interv Radiol 24:207-13. 2013
    ..To assess the safety and effectiveness of percutaneous cryoablation to treat limited metastases to the musculoskeletal system, with the goal of complete disease remission...
  37. pmc Capecitabine and temozolomide: design, implementation, and preliminary outcomes from a pilot project to ensure safe prescribing of oral chemotherapy
    Aminah Jatoi
    Division of Medical Oncology, Mayo Clinic, Rochester, MN
    J Oncol Pract 6:210-2. 2010
    ..Without adequate safety measures, oral chemotherapy can lead to undetected dosing errors. The Mayo Clinic launched a project to ensure that all capecitabine and temozolomide prescriptions receive an independent double check...
  38. ncbi request reprint Gemcitabine plus cisplatin in advanced pancreatic cancer
    Robert R McWilliams
    J Clin Oncol 25:1142; author reply 1142-3. 2007
  39. pmc Mitochondrial genetic polymorphisms do not predict survival in patients with pancreatic cancer
    Thorvardur R Halfdanarson
    Department of Internal Medicine, Division of Hematology, Oncology and Blood and Marrow Transplantation, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA
    Cancer Epidemiol Biomarkers Prev 17:2512-3. 2008
    ..After adjusting for covariates and multiple comparisons, no association between any of the mitochondrial single nucleotide polymorphisms or haplogroups and survival was observed...

Research Grants2

  1. Genetic Epidemiology of Young-Onset Pancreatic Cancer
    Robert McWilliams; Fiscal Year: 2007
    ..This proposed research is 100% relevant to pancreatic cancer. ..